Assessing Nanjing Leads Biolabs (SEHK:9887) Valuation After Recent Share Price Volatility
The Biotech Paradox: Betting on the Future vs. Current Losses Investing in clinical-stage biotechnology is less like traditional stock picking and more like venture capital. You aren’t buying current earnings; you are buying a “probability of success.” This is the central tension currently surrounding companies like Nanjing Leads Biolabs (SEHK:9887). For a firm focused on … Read more